Role of the Platelet in Type 2 Diabetes: Therapeutic Options

Release Date: Wednesday, October 20, 2021
Expiration Date: Friday, April 29, 2022

Launch Presentation (60 minutes) Download Handout

Platelet dysfunction is a key driver of thrombotic risk in people with type 2 diabetes and coronary artery disease. In this activity, the role of antiplatelet agents for primary and secondary prevention of cardiovascular (CV) events in people with T2D is reviewed, and guideline prevention recommendations are described.

Learning Objectives

  • Describe the impact of concurrent coronary artery disease (CAD) and type 2 diabetes (T2D).
  • Summarize the mechanisms involved in altered platelet function in people with CAD and T2D.
  • Use guideline recommendations to assess the need for antiplatelet therapy for primary and secondary prevention of cardiovascular events in people with T2D.

This webinar is not accredited for continuing education.


Andrew S. Bzowyckyj, Pharm.D., BCPS, CDCES
Associate Professor of Pharmacy Practice
Pacific University Oregon School of Pharmacy
Hillsboro, Oregon


In accordance with ACCME and ACPE Standards for Commercial Support, ASHP policy requires that all faculty, planners, reviewers, staff, and others in a position to control the content of this presentation disclose their financial relationships.

In this activity, no persons associated with this activity have disclosed any relevant financial relationships.

Target Audience

This activity was planned to meet the educational needs of pharmacists and pharmacist decision makers who care for or have an interest in the care of patients with type 2 diabetes.